Glimepiride (0.5 mg/day) Administration Improves Glycemic Control without Weight Gain in Japanese Type 2 Diabetic Patients
-
- Urakaze Masaharu
- Toyama University Hospital
-
- Yamazaki Katsuya
- Toyama University Hospital
-
- Usui Isao
- Toyama University Hospital
-
- Iwata Minoru
- Toyama University Hospital
-
- Uno Tatsuhito
- Toyama University Hospital
-
- Murakami Shihou
- Itoigawa General Hospital
-
- Yamamoto Yuki
- Asahi General Hospital
-
- Kishida Mika
- Saiseikai Toyama Hospital
-
- Aikawa Hidehiko
- Koshi Rehabilitation Hospital
-
- Kawahara Junko
- Toyama Red Cross Hospital
-
- Senda Satoko
- Toyama Red Cross Hospital
-
- Ishizuka Ken
- Toyama Red Cross Hospital
-
- Ikemoto Masahito
- Nunose Medical Clinic
-
- Sawazaki Shigeki
- Hida City Hospital
-
- Fukui Kazuhito
- Takaoka City Hospital
-
- Takano Atsuko
- Saiseikai Takaoka Hospital
-
- Yamazaki Yu
- Saiseikai Takaoka Hospital
-
- Hori Hiroyuki
- Saiseikai Takaoka Hospital
-
- Wada Osamu
- Shakaihoken Takaoka-Hospital
-
- Kamura Yutaka
- Shakaihoken Takaoka-Hospital
-
- Igarashi Yasuhito
- Hakuikan Hospital
-
- Sato Akira
- Hakuikan Hospital
-
- Fukushima Yasuo
- Nanto Municipal Hospital
-
- Takata Michiyo
- Himi Municipal Hospital
-
- Temaru Rie
- Nanto Municipal Hospital
-
- Ohgaku Seiji
- Ohgaku Clinic
-
- Akagawa Naoji
- Asahi General Hospital
-
- Kato Hiromi
- Himi Municipal Hospital
-
- Kobayashi Masashi
- Toyama University Hospital
Bibliographic Information
- Other Title
-
- 2型糖尿病患者に対する薬物療法開始薬剤としてのグリメピリド0.5 mg投与の有用性
- 2ガタ トウニョウビョウ カンジャ ニ タイスル ヤクブツ リョウホウ カイシ ヤクザイ ト シテノ グリメピリド 0 5mg トウヨ ノ ユウヨウセイ
Search this article
Abstract
Glimepiride, a sulfonylurea, is widely used at doses from 1 mg to 6mg to treat type 2 diabetes mellitus (T2DM). Doses of 0.5 mg per day are not normally considered as initial therapy and have not, to our knowledge, been formally studied in this setting. We designed a study to determine the efficacy and safety of glimepiride at 0.5 mg per day as first-line medical therapy for Japanese patients with mild T2DM (6.5%≤HbA1c<8.0%). Of 40 patients enrolled, 37 were evaluated for efficacy. Mean HbA1c decreased from 7.2% at baseline to 6.4% at 4 months; 54.5% of patients achieved HbA1c of<6.5% following treatment with a fixed dose of 0.5 mg/day for 4 months. Average weight did not change. Four cases of hypoglycemia occurred (1 asymptomatic, 3 symptomatic) but none was severe. No cases of hypoglycemia occurred within the first month of treatment. In conclusion, glimepiride at 0.5 mg per day is safe and effective as first-line medical treatment for patients with mild T2DM, reducing HbA1c with very few hypoglycemic symptoms and no weight gain.
Journal
-
- Journal of the Japan Diabetes Society
-
Journal of the Japan Diabetes Society 50 (12), 835-841, 2007
THE JAPAN DIABETES SOCIETY
- Tweet
Details 詳細情報について
-
- CRID
- 1390001204906056576
-
- NII Article ID
- 10021274507
-
- NII Book ID
- AN00166576
-
- ISSN
- 1881588X
- 0021437X
-
- NDL BIB ID
- 9346817
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL
- CiNii Articles
-
- Abstract License Flag
- Disallowed